TY - JOUR
T1 - Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
AU - Unknown
AU - De Zeeuw, Dick
AU - Akizawa, Tadao
AU - Audhya, Paul
AU - Bakris, George L.
AU - Chin, Melanie
AU - Christ-Schmidt, Heidi
AU - Goldsberry, Angie
AU - Houser, Mark
AU - Krauth, Melissa
AU - Lambers Heerspink, Hiddo J.
AU - McMurray, John J.
AU - Meyer, Colin J.
AU - Parving, Hans Henrik
AU - Remuzzi, Giuseppe
AU - Toto, Robert D.
AU - Vaziri, Nosratola D.
AU - Wanner, Christoph
AU - Wittes, Janet
AU - Wrolstad, Danielle
AU - Chertow, Glenn M.
AU - Toto, B.
AU - McCullough, P.
AU - Ivanovich, P.
AU - Ketteler, M.
AU - Lachin, J.
AU - McGill, J.
AU - Agarwal, R.
AU - Anker, S.
AU - Arenillas, J. F.
AU - Januzzi, J.
AU - Jardine, A.
AU - Kasner, S.
AU - Kissela, B.
AU - Kolansky, D.
AU - Mann, J.
AU - Thadhani, R.
AU - Champion de Crespigny, P.
AU - Chan, D. T.
AU - D'Almeida, E.
AU - Fraser, I.
AU - Gray, N.
AU - Holt, S.
AU - Irish, A.
AU - Isbel, N.
AU - Kerr, P.
AU - Packham, D.
AU - Phoon, R.
AU - Pollock, C.
AU - Roger, S.
AU - Wu, M.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to <30 ml per minute per 1.73 m2 of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. RESULTS: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 months. A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone methyl group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P=0.92). In the bardoxolone methyl group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed in 51 patients, and 19 patients died from cardiovascular causes. A total of 96 patients in the bardoxolone methyl group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P<0.001). Estimated GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl group, as compared with the placebo group. CONCLUSIONS: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial.
AB - BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to <30 ml per minute per 1.73 m2 of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. RESULTS: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 months. A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone methyl group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P=0.92). In the bardoxolone methyl group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed in 51 patients, and 19 patients died from cardiovascular causes. A total of 96 patients in the bardoxolone methyl group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P<0.001). Estimated GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl group, as compared with the placebo group. CONCLUSIONS: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial.
UR - http://www.scopus.com/inward/record.url?scp=84890946148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890946148&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1306033
DO - 10.1056/NEJMoa1306033
M3 - Article
AN - SCOPUS:84890946148
SN - 0028-4793
VL - 369
SP - 2492
EP - 2503
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 26
ER -
